About Prevtec Microbia

Prevtec Microbia is a Canadian biotechnology company specialized in the development of vaccines and other technologies that help fight against bacterial diseases in food animals. In a world where antibiotic use in animal production is increasingly controlled, we develop innovative alternatives to antibiotics. Our products represent sustainable solutions. Prevtec Microbia is an innovation-centric company that operates in many areas of the world through strategic alliances, particularly in Canada and Europe. Prevtec Microbia is proud to be part of the quest for better ways to feed the world.
$33 billion

Estimated value of the global animal health industry by 2020*

* Vetnosis

33

Number of countries where Coliprotec® F4 is approved for use

10+

We have been devising innovative solutions to challenges in livestock production for over a decade.

News
Prevtec Microbia Receives European Marketing Authorization for Coliprotec® F4/F18 E. coli bivalent live vaccine
12/01/2017
regulatory

Montreal, Quebec – January 12, 2017 – Prevtec Microbia Inc. is pleased to announce that its German subsidiary, Prevtec Microbia GmbH, received the market authorization from the European Commission for Coliprotec® F4/F18 in the European Union. Coliprotec® F4/F18 is the first single dose oral vaccine intended for active immunization of pigs against enterotoxigenic F4- and F18-positive Escherichia coli, the two most important agents of post-weaning…

+
Publication of the scientific paper on the efficacy of the Coliprotec® F4 vaccine in the journal Vaccine
01/12/2016
media

Prevtec Microbia is pleased to announce that the scientific paper on the efficacy of the Coliprotec® F4 vaccine is now published in the journal Vaccine. Immunogenicity and protective efficacy of a single-dose live non-pathogenic Escherichia coli oral vaccine against F4-positive enterotoxigenic Escherichia coli challenge in pigs

+
  •  

    Antimicrobial resistance (AMR) is resistance of a microorganism to an antimicrobial medicine to which it was originally sensitive. AMR occurs naturally but the phenomenon is hugely increased by excessive and inappropriate use of antimicrobial medicines and poor infection control practices in animals and humans.

     

     

    Source: European Commission, http://europa.eu/rapid/press-release_STATEMENT-15-6097_en.htm